Skip to main content
Premium Trial:

Request an Annual Quote

AnchorDx Receives CE Mark for Lung Cancer Early Diagnosis Test

NEW YORK – Chinese oncology diagnostics firm AnchorDx said Wednesday that its PulmoSeek lung cancer early detection assay, has received CE marking, with a reagents license issued by the Netherlands' CIBG of Ministry of Health, Welfare, and Sport.

PulmoSeek uses cell-free DNA methylation analysis to identify epigenetic patterns specific to malignant cells and is intended for cancer detection and diagnosis in individuals with pulmonary nodules between 5 and 30 millimeters. According to the Guangzhou, China-based company, prospective clinical data has previously shown the test to have 100 percent sensitivity in a subgroup of 6-to-20-millimeter nodules and 97 percent sensitivity for stage I tumors, outperforming CT scans in a study published last year.

The CE mark will allow the firm to promote its lung cancer assay for the first time in countries that recognize the classification.

In the long term, AnchorDx has said it intends to develop its technology to support screening tests for the early detection of six major cancer types.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.